CN106520773B - The aptamer WYZ-3 and its screening technique of ovarian mucinous cancer cell 3AO and application - Google Patents

The aptamer WYZ-3 and its screening technique of ovarian mucinous cancer cell 3AO and application Download PDF

Info

Publication number
CN106520773B
CN106520773B CN201611082747.1A CN201611082747A CN106520773B CN 106520773 B CN106520773 B CN 106520773B CN 201611082747 A CN201611082747 A CN 201611082747A CN 106520773 B CN106520773 B CN 106520773B
Authority
CN
China
Prior art keywords
cell
cancer cell
ovarian
aptamer
wyz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201611082747.1A
Other languages
Chinese (zh)
Other versions
CN106520773A (en
Inventor
吴冬
黄慧娟
何春妮
林朝雅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hubei Huajian Pharmaceutical Group Co ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201611082747.1A priority Critical patent/CN106520773B/en
Publication of CN106520773A publication Critical patent/CN106520773A/en
Application granted granted Critical
Publication of CN106520773B publication Critical patent/CN106520773B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1048SELEX
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57449Specifically defined cancers of ovaries
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/10Applications; Uses in screening processes
    • C12N2320/13Applications; Uses in screening processes in a process of directed evolution, e.g. SELEX, acquiring a new function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to the aptamer WYZ-3 of ovarian mucinous cancer cell 3AO a kind of and its screening technique and applications, the sequence of the acid aptamers WYZ-3 are as follows: 5 '-AGCTGCTATACTAGCTAAAGACCTGAGGTCCTTTGACGTTCCAGGTAGACTTGAAC CGTACCGTAGCGATAGCTAGCTT-3 ', its screening technique is based on SELEX screening technique, using ovarian serous cancer cell SKOV3 and normal ovarian epithelial cell IOSE as counter-selection cell, it is positive sieve cell with ovarian mucinous cancer cell 3AO, filter out the aptamer with ovarian mucinous cancer cell 3AO specific binding, it has high specific, high-affinity, it can close in vitro At and modification, chemical property is stable, pharmacokinetic property is good, non-immunogenicity the features such as.

Description

The aptamer WYZ-3 and its screening technique of ovarian mucinous cancer cell 3AO and Using
Technical field
The present invention relates to the aptamer WYZ-3 of ovarian mucinous cancer cell 3AO a kind of and its screening technique and applications.
Background technique
Sensibility difference and treatment outcome Chang Bujia of the ovarian mucinous cancer to chemotherapeutics.Therefore, it is necessary to using more More targetedly researchs are to seek the treatment method for more preferably improving ovarian mucinous cancer survival.In the diagnosis of oophoroma In, the main method of use includes B ultrasound, CT, MRI, celioscopy and blood serum tumor markers inspection, these diagnostic methods master If being based on morphological criteria, lack specificity marker relevant to ovarian mucinous cancer.In addition, all oophoromas generally use Identical treatment method, i.e. the complex treatment strategy of operative treatment combined chemotherapy, these treatment method less pertinences are ideal.Base In monoclonal antibody technique, the targeted therapy strategy developed in recent years shows in terms of improving ovarian mucinous cancer survival Unique advantage out, but some defects possessed by antibody itself, such as the otherness between immunogenicity, unstability, batch, Make that there is certain limitation in its practical application clinically.In conclusion finding the special of ovarian mucinous cancer cell Property identification molecule, be of great significance in the diagnosing and treating of tumour.
Summary of the invention
The purpose of the present invention is to provide a kind of ovarian mucinous cancer cell 3AO's with high specific and high-affinity Aptamer WYZ-3 and its screening technique and application.
The purpose of the present invention is achieved through the following technical solutions:
A kind of aptamer WYZ-3 of ovarian mucinous cancer cell 3AO, its sequence are as follows:
5’-AGCTGCTATACTAGCTAAAGACCTGAGGTCCTTTGACGTTCCAGGTAGACTTGAACCGTACCGTA GCGATAGCTAGCTT-3’
The screening technique of the aptamer WYZ-3 of the ovarian mucinous cancer cell 3AO, based on aptamer External SELEX screening technique (the phyletic evolution technology of index concentration ligand), with ovarian serous cancer cell SKOV3 and normal ovum Nest epithelial cell IOSE is positive sieve cell as counter-selection cell with ovarian mucinous cancer cell 3AO, is filtered out and ovarian mucinous The aptamer of cancer cell 3AO specific binding.
The application of the aptamer WYZ-3 of the ovarian mucinous cancer cell 3AO detects ovarian mucinous in preparation Application in the kit of cancer, molecular probe or targeting medium.
The application of the aptamer WYZ-3 of the ovarian mucinous cancer cell 3AO treats ovarian mucinous in preparation Application in the targeted therapy probe of cancer.
The application of the aptamer WYZ-3 of the ovarian mucinous cancer cell 3AO treats ovarian mucinous in preparation Application in cancer drug.
The application of the aptamer WYZ-3 of the ovarian mucinous cancer cell 3AO is thin in research ovarian mucinous cancer Application in cellular surface albumen.
The application of the aptamer WYZ-3 of the ovarian mucinous cancer cell 3AO is contaminated in ovarian carcinoma pathology In color, separation ovarian mucinous cancer cell in and the application in the relevant internal molecular imaging of ovarian neoplasm.
For the prior art, the present invention has the advantages that
1. aptamer WYZ-3 has the advantages that high specific, its specific recognition ovarian mucinous cancer cell 3AO does not have other ovarian cancer cells, normal ovarian epithelial cell etc. or with weaker identification function.
2. aptamer WYZ-3 also have high-affinity, can synthesize and modify in vitro, chemical property is stable, medicine generation is dynamic The features such as mechanical property is good, non-immunogenicity.
3. aptamer is in cellular biology of tumor, clinical trial diagnostics, molecular imaging new technology development and target It has broad application prospects and important learning value in terms for the treatment of.
4. the synthesis cost of aptamer WYZ-3 is low compared with the cost of Antibody preparation, and the period is short, favorable reproducibility.
Detailed description of the invention
Fig. 1 is the solution that aptamer WYZ-3 combination ovarian mucinous cancer cell 3AO is measured using flow cytometry Curve is drawn from constant.Dissociation constant Kd=30.8 ± 10.6nM.In Fig. 1, abscissa is DNA concentration (nM), and ordinate is Average fluorescent strength.
Fig. 2 is the offset using flow cytometry aptamer WYZ-3 to ovarian mucinous cancer cell 3AO.? In Fig. 2, abscissa is fluorescence intensity, and ordinate is number of cells, and solid line WYZ-3, dotted line is unscreened single stranded DNA text Library.
Fig. 3 is the offset using flow cytometry aptamer WYZ-3 to ovarian serous cancer cell SKOV3. In Fig. 3, abscissa is fluorescence intensity, and ordinate is number of cells, and solid line WYZ-3, dotted line is unscreened single stranded DNA Library.
Fig. 4 is the offset using flow cytometry aptamer WYZ-3 to normal ovarian epithelial cell IOSE.? In Fig. 4, abscissa is fluorescence intensity, and ordinate is number of cells, and solid line WYZ-3, dotted line is unscreened single stranded DNA text Library.
Fig. 5 is the space structure schematic diagram of aptamer WYZ-3.
Specific embodiment
The content of present invention is described in detail with embodiment with reference to the accompanying drawings of the specification:
A kind of aptamer WYZ-3 of ovarian mucinous cancer cell 3AO, its sequence are as follows:
5’-AGCTGCTATACTAGCTAAAGACCTGAGGTCCTTTGACGTTCCAGGTAGACTTGAACCGTACCGTA GCGATAGCTAGCTT-3’
The aptamer WYZ-3 of the ovarian mucinous cancer cell 3AO, at 37 DEG C, 0.137M Na+, 0.001M Mg2+Physiological condition under, with characteristic loop-stem structure, space structure is as follows:
The aptamer WYZ-3 of the ovarian mucinous cancer cell 3AO, to the 5 ' of the aptamer WYZ-3 End or 3 ' ends carry out FITC, amino, biotin or digoxin chemical modification.
The screening technique of the aptamer WYZ-3 of the ovarian mucinous cancer cell 3AO, based on aptamer External SELEX screening technique, using ovarian serous cancer cell SKOV3 and normal ovarian epithelial cell IOSE as counter-selection cell, It is positive sieve cell, is filtered out suitable with the nucleic acid of ovarian mucinous cancer cell 3AO specific binding with ovarian mucinous cancer cell 3AO Ligand.
It is screening target cell using ovarian mucinous cancer cell 3AO, with corresponding ovarian serous cancer cell SKOV3 and normal ovarian epithelial cell IOSE as counter-selection cell, screening remove in DNA oligonucleotide library with ovary slurries Property cancer cell, normal ovarian epithelial cell non-specific binding part, guarantee that the obtained aptamer of screening can be special The combination ovarian mucinous cancer cell 3AO of property.
In addition, keeping the form of screening cell and activity intact using the Cell-SELEX screening technique of standard, guarantee thin Cellular surface large biological molecule is closer to the intracorporal molecular conformation of biology.
The screening technique of the aptamer WYZ-3 of the ovarian mucinous cancer cell 3AO, it the following steps are included:
(1) prepare single-stranded DNA banks shown in following sequence:
Single-stranded DNA banks:
5’-AGCTGCTATACTAGCTAAAGNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCCGTA GCGATAGCTAGCTT-3';
(2) SKOV3 cell counter-selection: the library that step (1) is prepared and SKOV3 cell incubation are collected thin after the completion of being incubated for Supernatant after born of the same parents' incubation;
(3) IOSE cell counter-selection: by supernatant obtained by step (2) and IOSE cell incubation, cell is collected after the completion of being incubated for and is incubated Supernatant after educating;
(4) 3AO cell just sieves: by step (3) resulting supernatant and 3AO cell incubation, after the completion of incubation, abandoning supernatant; It washs 3AO cell and by after under 3AO cell scraper, is transferred in EP pipe and carries out heat denatured, supernatant is collected in centrifuge separation later;
(5) PCR is enriched with: the resulting supernatant of step (4) carries out PCR amplification, obtains pcr amplification product;Wherein PCR amplification Primer used are as follows:
Primers F up:5 '-FAM-AGCTGCTATACTAGCTAAAG-3 ';
Primer Ldown:5 '-TTTTTTTTTTTTTTTTTTTTTTT-spacer C9-AAGCTAGCTATCGCTACGG- 3';
TTTTTTTTTTTTTTTTTTTTTTT-spacer C9 keeps the chain length of two primers different, produces convenient for PCR amplification The denaturing electrophoretic of object separates.
(6) single stranded DNA purifies: after pcr amplification product is carried out denaturation unwinding, denaturing electrophoretic separation, and purified pool FAM mark The ssDNA of note;
(7) aptamer Cycle Screening: the secondary library that step (6) resulting ssDNA is screened as next round, and Repeat the screening process of step (2)~(6).
Embodiment one: the screening of aptamer WYZ-3:
The screening technique of the aptamer WYZ-3 of the ovarian mucinous cancer cell 3AO, it the following steps are included:
(1) preparation in library is screened:
Synthesizing single-stranded DNA library (the 5 '-AGCTGCTATACTAGCTAAAGN of student on commission's work bioengineering limited liability company NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCCGTAGCGATAGCTAGCTT-3');Take that 1 pipe 1OD's is single-stranded DNA library, high speed centrifugation 2min;Pipe lid is gently opened in vent cabinet, and 300 μ L combination buffers are added and (contain 4.5g/ in DPBS L glucose, 100mg/L yeast tRNA, 1g/L BSA, 5mM MgCl2), vortex oscillation dissolution;Seal with sealing film centrifuge tube Lid, 95 DEG C of water-baths 5min, rapid ice-water bath 2min;High speed centrifugation 2min, it is spare.
(2) the library sucking SKOV3 cell growth coverage that step (1) prepares SKOV3 cell counter-selection: is reached about 60% In the diameter 100mm culture dish of left and right, 1mL is supplied with combination buffer;4 DEG C of shaking tables vibrate 1h;By supernatant 1000rpm from Heart 10min collects supernatant;
(3) IOSE cell counter-selection: supernatant obtained by aspiration step (2) to IOSE cell growth coverage reaches about 60% or so Diameter 100mm culture dish in;4 DEG C of shaking tables vibrate 1h;Supernatant 1000rpm is centrifuged 10min, collects supernatant;
(4) 3AO cell just sieves: aspiration step (3) resulting supernatant to 3AO cell growth coverage reaches about 60% or so Diameter 60mm culture dish in, 4 DEG C of shaking tables vibrate 1h;Abandon supernatant;With washing buffer (glucose containing 4.5g/L in DPBS, 5mM MgCl2) washing 3AO cell three times;With cell scraper by under 3AO cell scraper, 3AO cell is shifted with 1mL washing buffer Into EP pipe, 95 DEG C of water-baths 5min, rapid ice-water bath 2min;10000rpm is centrifuged 5min, leaves and takes supernatant.
(5) PCR is enriched with: being taken 50 μ L step (4) resulting Supernatant samples, is added in 1mL PCRmix;Vortex oscillation is mixed After even, dispensed by every 50 μ L of pipe and carry out PCR amplification, amplification condition are as follows: after 95 DEG C of heating initial denaturation 10min, 94 DEG C of denaturation 30s, 60 DEG C of annealing 30s, 72 DEG C of extension 30s, 25 recycle.
Wherein contain in 1mL PCRmix: H2O 871μL;10 × PCR buffer, 100 μ L;
Primers F up:5 '-FAM-AGCTGCTATACTAGCTAAAG-3 ' and Ldown:5 '- Each 3 μ L of TTTTTTTTTTTTTTTTTTTTTTT-spacer C9-AAGCTAGCTATCGCTACGG-3 ';3 μ L of pfu enzyme;dNTP 20μL.The equal student on commission's work bioengineering limited liability company synthesis of the primers F up and primer Ldown.
(6) single stranded DNA purifies: pcr amplification product is mixed, the n-butanol of 6 times of volumes is added, vortex concussion mixes, 14000rpm, room temperature are centrifuged 10min;About 50 μ L of suction foot sample, mixes, 95 DEG C in equal volume with TBE/7M Urea buffer Water-bath 10min, rapid ice-water bath 2min;With the urea-denatured polyacrylamide gel electrophoresis separation (400V voltage) of 7M;Electrophoresis knot Shu Hou, in fluoroscopic imaging systems, the ssDNA band of gel extraction FAM label;Gel is shredded, 500 μ L ddH are added2O, 10min is boiled, high speed centrifugation collects supernatant;2.5 times of volume ethanols are added, are placed at room temperature for 15min, high speed centrifugation abandons supernatant, sinks It forms sediment and is dissolved with 100 μ L combination buffers.
(7) aptamer Cycle Screening: the secondary library that step (6) resulting ssDNA is screened as next round, and Repeat the screening process of step (2)~(6).
Embodiment two: the analysis of aptamer WYZ-3 sequence:
After 12 wheel screenings, recycling 3AO cell just sieves supernatant, and entrusts the upper gloomy limited public affairs of promise biotechnology share of the Shanghai's style Department analyzes library sequence using high throughput sequencing technologies, analytic process are as follows: PCR amplification enriched library, and plus sequencing Connector and the part Index;Purified library is selected by gel electrophoresis;Passed through using Agilent 2100Bioanalyzer Agilent High Sensitivity DNAKit is to library Quality Control;Utilize Quant-iT PicogGreen dsDNA Assay Kit quantifies library;Using 500 platform of IlluminateNextSeq, bridge-type PCR expansion is carried out by template of single-stranded library Increase, sequencing primer is annealed, is sequenced in synthesis;And analysis is compared and is enriched with to sequencing result.
Using the UNAFold network platform analysis in physiological conditions (37 DEG C, 0.137M Na+, 0.001M Mg2+), the core The secondary structure of sour aptamers WYZ-3 sequence.Analyze secondary structure schematic diagram such as Fig. 5 institute of aptamer WYZ-3 sequence Show.
Embodiment three: the analysis of aptamer WYZ-3 and ovarian mucinous cancer cell 3AO binding ability:
1. target cell 3AO is inoculated in 24 orifice plates (50,000/hole), in 37 DEG C, 5%CO2Culture is for 24 hours.
2. single stranded DNA (including the aptamer WYZ-3 and unscreened single-stranded for being marked FITC with combination buffer DNA library) it is configured to the solution that concentration is 0nM, 10nM, 50nM, 100nM, 200nM;95 DEG C of water-bath 5min, rapid ice-water bath 2min。
3. washing cell twice with combination buffer, the single stranded DNA solution of the 200 above-mentioned gradient concentrations of μ L is added in every hole, and It is placed in and is incubated for 30min on ice.
4. after being incubated for, abandoning supernatant, being swept cell with cell scraper;It is washed twice with combination buffer, cell is resuspended, body Product is 250 μ L.
5. the FACSAria flow cytometer using BD company carries out fluoremetry to cell;Measurement result GraphPad The mapping of 6 software of Prism, the dissociation constant for calculating gained aptamer WYZ-3 is 30.8 ± 10.6nM, as shown in Figure 1. The testing result of Fig. 1 shows: aptamer WYZ-3 and the binding ability of target cell ovarian mucinous cancer cell 3AO are strong, dissociation Constant is in nanomole rank.
Example IV: the analysis of aptamer WYZ-3 and ovarian mucinous cancer cell 3AO binding specificity:
1. count cell to be measured to be simultaneously inoculated in 24 orifice plates (50,000/hole), in 37 DEG C, 5%CO2Culture is for 24 hours.
2. wash cell twice with combination buffer, the single stranded DNA of 200 μ L FITC label is added in every hole, and (including nucleic acid is suitable Ligand WYZ-3 and unscreened single-stranded DNA banks), it is placed in and is incubated for 30min on ice.
3. after being incubated for, abandoning supernatant, being swept cell with cell scraper;It is washed twice with combination buffer, cell is resuspended, body Product is 250 μ L.
4. the FACSAria flow cytometer using BD company carries out fluoremetry to cell.
The cell to be measured is respectively ovarian mucinous cancer cell 3AO, ovarian serous cancer cell SKOV3 and normal Ovarian epithelial cell IOSE, wherein ovarian serous cancer cell SKOV3 and normal ovarian epithelial cell IOSE is that control is thin Born of the same parents, testing result is as shown in figs. 2 to 4.It is proved by the testing result of the flow cytometry of Fig. 2~4, aptamer of the invention WYZ-3 has stronger specific recognition capability to ovarian mucinous cancer cell 3AO, and thin to control cell ovarian serous carcinoma Born of the same parents SKOV3 and normal ovarian epithelial cell IOSE are without identification.
SEQUENCE LISTING
<110>Wu's winter
<120>the aptamer WYZ-3 of ovarian mucinous cancer cell 3AO and its screening technique and application
<160> 3
<210> 1
<211> 79
<212> DNA
<213>artificial sequence
<400> 1
agctgctata ctagctaaag acctgaggtc ctttgacgtt ccaggtagac 50
ttgaaccgta ccgtagcgat agctagctt 79
<210> 2
<211> 20
<212> DNA
<213>artificial sequence
<400> 2
agctgctata ctagctaaag 20
<210> 3
<211> 19
<212> DNA
<213>artificial sequence
<400> 3
aagctagcta tcgctacgg 19

Claims (4)

1. a kind of aptamer WYZ-3 of ovarian mucinous cancer cell 3AO, it is characterised in that: its sequence is as follows:
5’-AGCTGCTATACTAGCTAAAGACCTGAGGTCCTTTGACGTTCCAGGTAGACTTGAACCGTACCGTAGCGA TAGCTAGCTT-3’。
2. the aptamer WYZ-3 of ovarian mucinous cancer cell 3AO according to claim 1, it is characterised in that: 37 DEG C, 0.137M Na+, 0.001M Mg2+Under the conditions of its space structure it is as follows:
3. the aptamer WYZ-3 of ovarian mucinous cancer cell 3AO according to claim 1, it is characterised in that: to institute 5 ' the ends or 3 ' ends for stating aptamer WYZ-3 carry out FITC, amino, biotin or digoxin chemical modification.
4. the aptamer WYZ-3 of ovarian mucinous cancer cell 3AO described in claim 1-3 any one is detected in preparation Application in the kit of ovarian mucinous cancer, molecular probe or targeting medium.
CN201611082747.1A 2016-11-30 2016-11-30 The aptamer WYZ-3 and its screening technique of ovarian mucinous cancer cell 3AO and application Active CN106520773B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611082747.1A CN106520773B (en) 2016-11-30 2016-11-30 The aptamer WYZ-3 and its screening technique of ovarian mucinous cancer cell 3AO and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611082747.1A CN106520773B (en) 2016-11-30 2016-11-30 The aptamer WYZ-3 and its screening technique of ovarian mucinous cancer cell 3AO and application

Publications (2)

Publication Number Publication Date
CN106520773A CN106520773A (en) 2017-03-22
CN106520773B true CN106520773B (en) 2019-01-25

Family

ID=58355390

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611082747.1A Active CN106520773B (en) 2016-11-30 2016-11-30 The aptamer WYZ-3 and its screening technique of ovarian mucinous cancer cell 3AO and application

Country Status (1)

Country Link
CN (1) CN106520773B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107312779B (en) * 2017-03-24 2020-11-17 领航基因科技(杭州)有限公司 Aptamers for isolating trophoblast cells, methods of isolating trophoblast cells, and methods of analyzing chromosomal copy number variations
CN113481205B (en) * 2021-07-30 2023-11-03 杭州凡泰生物科技有限公司 Aptamer HPV1801 of HPV18 virus particle and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104988154A (en) * 2015-06-24 2015-10-21 中国科学院化学研究所 Application of nucleic acid aptamers in identifying and being bound with integrin alpha4
CN105044322A (en) * 2015-06-24 2015-11-11 中国科学院化学研究所 Application of aptamer in recognition of L selectin and combination with L selectin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104988154A (en) * 2015-06-24 2015-10-21 中国科学院化学研究所 Application of nucleic acid aptamers in identifying and being bound with integrin alpha4
CN105044322A (en) * 2015-06-24 2015-11-11 中国科学院化学研究所 Application of aptamer in recognition of L selectin and combination with L selectin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
《An on-chip Cell-SELEX process for automatic selection of high-affinity aptamers specific to differenthistologically classified ovarian cancer cells》;Hung Lien-Yu等;《Lab on a chip》;20141021;第14卷(第20期);第4017-4028页
《Study of the Molecular Recognition of Aptamers Selected through Ovarian Cancer Cell-SELEX》;Van Simaeys D等;《Plos one》;20101101;第5卷(第11期);第1-7页
《全细胞的核酸适配体筛选的研究进展》;刘品多等;《色谱》;20160430;第34卷(第4期);第382-388页

Also Published As

Publication number Publication date
CN106520773A (en) 2017-03-22

Similar Documents

Publication Publication Date Title
CN106591313B (en) The aptamer WYZ-1 and its screening technique of ovarian mucinous cancer cell 3AO and application
CN109806275B (en) Application of DNA tetrahedron in preparation of nerve repair promoting medicine
JP2015524054A5 (en)
CN106970224B (en) A kind of kit and its application using CD45 immunofluorescences joint CEP probe identification circulating tumor cells
CN110004147A (en) A kind of aptamer and its preparation method and application of the epithelial cell adhesion molecule EpCAM screened in human plasma
CN110117595A (en) It is a kind of specifically bind PDL1 aptamer and its application
CN106520773B (en) The aptamer WYZ-3 and its screening technique of ovarian mucinous cancer cell 3AO and application
Koczkodaj et al. Examination of clonal evolution in chronic lymphocytic leukemia
CN106957906A (en) A kind of primer combination and kit that T cell Minimal Residual Disease of Leukemia is detected applied to high-flux sequence
JP2024023284A (en) Methods of using giant cell nucleic acid characterization in cancer screening, diagnostics, treatment and recurrence
CN106480017A (en) Extract the test kit of circulating tumor cell DNA and tumor dissociative DNA simultaneously
CN106754936B (en) The aptamer WYZ-2 and its screening technique of ovarian mucinous cancer cell 3AO and application
CN108342478B (en) Circulating tumor cell metabolism typing marker and application thereof
CN112877333A (en) Aptamer for specifically recognizing integrin beta 3 subunit protein and application thereof
CN106591314B (en) The aptamer WYZ-4 and its screening technique of ovarian mucinous cancer cell 3AO and application
CN106754935B (en) The aptamer WYZ-5 and its screening technique of ovarian mucinous cancer cell 3AO and application
CN105755135B (en) A kind of No. 17 chromosome centromere probe reagent boxes of people and its preparation method and application
CN108866064A (en) A kind of aptamer of targeted metastatic human breast cancer cell and its application
Popovic Routine and novel methods for isolation of extracellular vesicles
CN108265055A (en) Specifically bind DNA aptamers and its application of human breast cancer cell line Bcap-37
KR101704828B1 (en) Method for diagnosing inflammatory diseases through analysis of protein or gene of extracellular vesicle in a body fluid
CN109266653B (en) Reagent, device and method for capturing drug-resistant heterogeneous circulating tumor cells and performing gene analysis
CN104651522B (en) The new opplication of 1 chain of type i collagen α
WO2022242285A1 (en) Method for separating placental trophoblast cells from exfoliated cervical cells of pregnant woman
CN114990125A (en) Aptamer capable of specifically recognizing positive PD-L1 and preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20211202

Address after: 314500 Tongxiang, Jiaxing, Zhejiang, Wutong Street East Road (East) 55, Tongxiang chamber of Commerce Building 1 unit 1702, 1703 room -D-404

Patentee after: Jiaxing Huiquan Biotechnology Co.,Ltd.

Address before: 350200 room 103, No. 2, Nanshan business building, Changle City, Fuzhou City, Fujian Province

Patentee before: Wu Dong

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240402

Address after: Room 1018-15, Building 23, Times Square, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Suzhou City, Jiangsu Province, 215000

Patentee after: Suzhou 30 billion Technology Co.,Ltd.

Country or region after: China

Address before: 314500 Tongxiang, Jiaxing, Zhejiang, Wutong Street East Road (East) 55, Tongxiang chamber of Commerce Building 1 unit 1702, 1703 room -D-404

Patentee before: Jiaxing Huiquan Biotechnology Co.,Ltd.

Country or region before: China

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240715

Address after: Room 201, Unit 1, Building 1, Group 1, Xiaochangpo Village, Chengguan Town, Yunxi County, Shiyan City, Hubei Province, 442000

Patentee after: Hubei Huajian Pharmaceutical Group Co.,Ltd.

Country or region after: China

Address before: Room 1018-15, Building 23, Times Square, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Suzhou City, Jiangsu Province, 215000

Patentee before: Suzhou 30 billion Technology Co.,Ltd.

Country or region before: China

TR01 Transfer of patent right